Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
about
Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamusAltered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence?Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesLiraglutide and obesity: a review of the data so far.Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference BehaviorTreatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.GLP-1 based therapeutics: simultaneously combating T2DM and obesity.Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study.Exposure-response analyses of liraglutide 3.0 mg for weight management.Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Pharmacotherapy for obesity: novel agents and paradigms.The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Extra-pancreatic effects of incretin-based therapies.Liraglutide in the treatment of obesity.Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.New molecular targets in the pathophysiology of obesity and available treatment options under investigation.Latest approaches for the treatment of obesity.Liraglutide: an injectable option for the management of obesity.Liraglutide for Type 2 diabetes and obesity: a 2015 update.Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.Epidemiology of Obesity and Pharmacologic Treatment Options.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.Albiglutide: a unique GLP-1 receptor agonist.A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.The safety of albiglutide for the treatment of type 2 diabetes.Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.European Guidelines for Obesity Management in Adults.Modeling energy intake and body weight effects of a long-acting amylin analogue.Aversion learning can reduce meal size without taste avoidance in rats.Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.
P2860
Q26749191-1F341F54-8512-49BD-B179-95BEF9FBB693Q26779389-E35A7F84-9970-49A3-BEA1-6D86FAAE4B75Q28067465-266E9EF3-02B9-4C9C-938F-4744F60EBD86Q30924982-F9CC0FAF-2BB1-495E-BE91-81F796127982Q34501087-419940C8-99CC-4A01-8DF8-E9105013E5C9Q34665186-3D95579D-2AEB-40DB-A926-44028F50A73CQ34745109-F142F339-F992-4176-9CF6-0A2B3C71A252Q35200252-7639ABA1-8763-4AB3-8CB1-6776E9EF35DFQ36265522-19A27342-6F37-4DF6-9361-E9C00F51257EQ36741706-80742AEB-48FF-4315-9B12-8839A1176A3EQ37348898-ED5F0A0B-65E9-4825-B4D3-EB9E0FD7FDD1Q37456486-A0BE85E6-C87B-448C-9822-C16A8C5CD039Q37568754-E99FA83B-C4EA-49F4-B19F-413335F45719Q37712227-4A87A212-FD78-43D8-A2FE-DD02F38470D9Q38174279-05B55AF7-972A-446E-AB38-76B8FF4652C1Q38194069-7BDEBE0C-C1FE-4487-B28C-53F66CA8B9C2Q38218159-8B9482DB-252D-4FA9-8BEE-0A5C55435531Q38254745-ED9B3F4E-5254-4886-B8C4-F75574277601Q38397535-00F201E3-60D7-4769-8C22-C5E9AC8B5592Q38475978-EB42A354-AD54-4109-937E-D1282FC7BCB2Q38488897-40F4F0DC-0B13-4AEE-B53E-E7D67FC351B1Q38536672-BFF6DA14-7A00-4541-90B9-664C8BEC19E3Q38542098-26EB1538-0080-4AB2-986F-8A8E3AA7BBC8Q38717129-9B8009D2-4483-4537-9E79-873A76E5504DQ38758765-761E2A7A-F0BF-4472-9618-F2FA0CE9A7CAQ38794395-323F6813-2D43-45DE-9CC9-6526CBBCD5DDQ38937735-9436E33B-0392-48E2-A162-E79CE6786EB9Q38966029-2DAC6411-66FC-4FAB-A274-6E0A4B6E88D1Q39008520-8639E4D1-E528-4899-8DDE-44CB79CF23EDQ39415439-BCF3814F-5730-4726-8CD8-54D81F02A62FQ40815972-B7E699EE-3AE9-4D66-8E05-9B722ABF44B6Q47094048-907BF929-0640-4BA6-95FF-0BCAA17B7D2FQ47175680-F811439B-5D86-40FE-BA73-DC5E03CDD75CQ47328876-5B11F758-445D-432C-978C-0D06689EE878Q47386368-25D4D6C4-1BA0-428D-820A-EA559162E0B8Q48130202-BA500EC1-EA2C-4561-9340-0D3BA6856D46Q49962233-EC2CE9D4-3507-488E-BAB4-D0A334F64BD8
P2860
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@ast
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@en
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@nl
type
label
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@ast
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@en
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@nl
prefLabel
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@ast
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@en
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@nl
P2093
P2860
P50
P356
P1476
Tolerability of nausea and vom ...... in obese, non-diabetic adults.
@en
P2093
L Van Gaal
M E J Lean
M L Lindegaard
NN8022-1807 Investigators
P2860
P2888
P304
P356
10.1038/IJO.2013.149
P407
P577
2013-08-14T00:00:00Z
P5875
P6179
1044671187